- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05090371
A Multicenter Study of Continued Current Therapy vs Transition to Ofatumumab After Neurofilament (NfL) Elevation (SOSTOS)
A Randomized, Open Label, Multi-center, Active-comparator Study to Assess Efficacy, Safety & Tolerability of Ofatumumab 20mg sc Monthly Versus Continued Current Therapy in Relapsing-remitting Multiple Sclerosis After Elevation of Serum Neurofilament Light Levels (SOSTOS)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a multicenter, prospective study of up to 150 relapsing-remitting MS participants/ The study is looking to see if patients who have not had a relapse in the past year would benefit from switching to ofatumumab.
After giving consent, participants will have a 1 week screening/qualification period. If they qualify to continue, they will start a a six month run-in period during which lab samples will be collected. Patients that are relapse-free during the run-in period will continue into next period of the study in which they will be randomized to either ofatumumab or continued therapy for the next 15 months. Every 3 out of 5 randomized participants will be selected to wear a digital study watch to collect physical activity, sleep, and vitals during this 15 month period. The study watch will be worn 24 hours a day, 7 days a week but can be removed during showers/bathing. At the end of the 15 month period, a study completion visit will be held.
The total study duration is 21 months plus 1 week for screening/qualification.
Study Type
Enrollment (Estimated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Novartis Pharmaceuticals
- Phone Number: 1-888-669-6682
- Email: novartis.email@novartis.com
Study Contact Backup
- Name: Novartis Pharmaceuticals
- Phone Number: +41613241111
Study Locations
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V6T 2B5
- Recruiting
- Novartis Investigative Site
-
-
Quebec
-
Granby, Quebec, Canada, J2G 1T7
- Recruiting
- Novartis Investigative Site
-
Levis, Quebec, Canada, G6W 0M5
- Recruiting
- Novartis Investigative Site
-
-
-
-
Alabama
-
Birmingham, Alabama, United States, 35209
- Recruiting
- Novartis Investigative Site
-
Cullman, Alabama, United States, 35058
- Recruiting
- Novartis Investigative Site
-
-
Arizona
-
Phoenix, Arizona, United States, 85032
- Recruiting
- Novartis Investigative Site
-
-
California
-
Torrance, California, United States, 90509-2004
- Recruiting
- Novartis Investigative Site
-
-
Florida
-
Altamonte Springs, Florida, United States, 32714
- Recruiting
- Novartis Investigative Site
-
Maitland, Florida, United States, 32751
- Recruiting
- Novartis Investigative Site
-
Miami, Florida, United States, 33032
- Recruiting
- Novartis Investigative Site
-
Orlando, Florida, United States, 32806
- Recruiting
- Novartis Investigative Site
-
Pensacola, Florida, United States, 32514
- Recruiting
- Novartis Investigative Site
-
Tampa, Florida, United States, 33612
- Recruiting
- Novartis Investigative Site
-
-
Idaho
-
Coeur d'Alene, Idaho, United States, 83815
- Recruiting
- Novartis Investigative Site
-
-
Louisiana
-
Alexandria, Louisiana, United States, 71301
- Recruiting
- Novartis Investigative Site
-
-
Maryland
-
Lutherville, Maryland, United States, 21093
- Recruiting
- Novartis Investigative Site
-
-
Massachusetts
-
Worcester, Massachusetts, United States, 01608
- Recruiting
- Novartis Investigative Site
-
-
Michigan
-
Detroit, Michigan, United States, 48202 2689
- Recruiting
- Novartis Investigative Site
-
Owosso, Michigan, United States, 48867
- Recruiting
- Novartis Investigative Site
-
-
Mississippi
-
Jackson, Mississippi, United States, 39216
- Recruiting
- Novartis Investigative Site
-
-
New Jersey
-
Neptune, New Jersey, United States, 07753
- Recruiting
- Novartis Investigative Site
-
-
New York
-
Syracuse, New York, United States, 13210
- Recruiting
- Novartis Investigative Site
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27599-9500
- Recruiting
- Novartis Investigative Site
-
Charlotte, North Carolina, United States, 28210
- Recruiting
- Novartis Investigative Site
-
Raleigh, North Carolina, United States, 27607
- Recruiting
- Novartis Investigative Site
-
-
Tennessee
-
Knoxville, Tennessee, United States, 37922
- Recruiting
- Novartis Investigative Site
-
-
Texas
-
Houston, Texas, United States, 77074
- Recruiting
- Novartis Investigative Site
-
Lubbock, Texas, United States, 79410
- Recruiting
- Novartis Investigative Site
-
Webster, Texas, United States, 77598
- Recruiting
- Novartis Investigative Site
-
-
Virginia
-
Virginia Beach, Virginia, United States, 23456
- Recruiting
- Novartis Investigative Site
-
-
Washington
-
Kirkland, Washington, United States, 98034
- Recruiting
- Novartis Investigative Site
-
Seattle, Washington, United States, 98122-4379
- Recruiting
- Novartis Investigative Site
-
-
Wisconsin
-
Green Bay, Wisconsin, United States, 54311
- Recruiting
- Novartis Investigative Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Signed informed consent must be obtained prior to participation in the study.
- Age 18-45 years
- Diagnosis of RRMS per McDonald Criteria (2017)
- EDSS 0-5.5 (Inclusive)
- Able to obtain MRI and attend study visits at sites
- Willing to use wearable device as specified in the protocol
- Able to provide blood sample
- On a current DMT with approved label use for treatment of RRMS at least 6 months prior to Screening
- No relapse reported within 6 months prior to Screening
- Patients may enroll in the trial if they have subclinical disease activity as measured by MRI prior to enrollment. An absence of MRI activity is not exclusionary.
Exclusion Criteria:
- Primary progressive or secondary progressive phenotype
- Diseases other than multiple sclerosis responsible for the clinical or MRI presentation
- Use of experimental or investigational drugs for MS within 2 years from Screening
- Known sensitivity to gadolinium
- Central Nervous System (CNS) anomalies that are better accounted for by another disease process
- Known active malignancies
- Active chronic disease (or stable but treated with immune therapy) of the immune system other than MS
- Active infections including systemic bacterial, viral (including COVID-19) or fungal infections, known to have AIDS or tested positive for HIV antibodies
- Neurological findings consistent with Progressive Multifocal Leukoencephalopathy (PML), or confirmed PML
- IgG or IgM levels below lower limit of normal (LLN) at Screening
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Ofatumumab
20 mg
|
3 loading doses followed by administration every 4 weeks as per label
|
Active Comparator: DMT continued therapy
Participants randomized to the continued therapy arm will continue to take their disease modifying treatment (DMT) as prescribed commercially by their physician.
|
Other DMT with approved label use for treatment which participants were on at least 6 months prior to Screening
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of participants achieving NEDA-3 (No Evidence of Disease Activity-3)
Time Frame: Months 3 to 15
|
A participant is considered as achieved NEDA-3 if the participant has not had a clinical relapse (recurrence of a disease activity after a recovery), has not had an increase in disability and has no new radiological MRI activity (no new occurrences of contrast-enhancing lesions) during study Months 3 to 15.
|
Months 3 to 15
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of participants with a single baseline NfL≥10pg/ml and NfL<10pg/ml achieving NEDA-3 (No Evidence of Disease Activity-3)
Time Frame: Months 3 to15
|
Participants with a single baseline NfL≥10 pg/ml and NfL<10pg/ml will be considered as achieved NEDA-3 if the participant has not had a clinical relapse (recurrence of a disease activity after a recovery), has not had an increase in disability and has no new radiological MRI activity (no new occurrences of contrast-enhancing lesions)
|
Months 3 to15
|
Annualized relapse rate in Months 3 to 15
Time Frame: Months 3 to 15
|
Relapses are recurrences of a disease activity after a recovery.
A confirmed MS relapse is one accompanied by a clinically relevant change in the EDSS performed by the EDSS Rater, i.e. an increase of at least 0.5 points on the EDSS score, or an increase of 1 point on two functional scores (FSs) or 2 points on one FS, excluding changes involving bowel/bladder or cerebral FS compared to the previous available rating (the last EDSS rating that did not occur during a relapse).
Confirmation of MS relapse based on these definitions will be done centrally.
|
Months 3 to 15
|
Percentage of participants without a worsening of their disability
Time Frame: Months 3 to 15
|
No increase or worsening of disability
|
Months 3 to 15
|
Percentage of participants with NEDA (No Evidence of Disease Activity) - Clinical
Time Frame: Months 3 to 15
|
A participant is considered as achieved NEDA-clinical is no clinical relapse or disease progression (by EDSS) has occurred.
|
Months 3 to 15
|
Percentage of participants with NEDA (No Evidence of Disease Activity) - Radiological
Time Frame: Months 3 to 15
|
A participant is considered as achieved NEDA-radiological if the participant has has no new radiological MRI activity (no new occurrences of contrast-enhancing lesions) during study Months 3 to 15.
|
Months 3 to 15
|
Mean change in The Symbol-Digit Modality Test
Time Frame: Baseline, Months 3 and 15
|
This test measures cognition in patients with MS.
Patients are asked to substitute a number, either orally or written, for randomized presentations of geometric figures.
|
Baseline, Months 3 and 15
|
Mean change in the Time 25 Foot Walk
Time Frame: Baseline, Months 3 and 15
|
This is a test of mobility and leg function.
The patient is instructed to one end of a marked 25-foot course and is instructed to walk 25 feet as quickly as possible, but safely.
The time to complete the test is calculated from the initiation of the instruction to start and ends when the patient has reached the 25-foot mark.
The task is performed again when the patient is directed to walk back the same distance.
A walking device is permitted during this test.
|
Baseline, Months 3 and 15
|
Mean change in the 9 Hole Peg Test
Time Frame: Baseline, Months 3 and 15
|
This is a test of upper extremity function.
The patient is seated at a table with a small, shallow container holding nine pegs and a wood or plastic block containing nine empty holes.
The patient picks up the nine pegs one at a time as quickly as possible, puts them in nine holes and once they are in the holes, the patient removes them again as quickly as possible one at a time, replacing them into the shallow container.
The total time to complete the task is recorded.
This test is performed with both the dominant and non-dominant hand.
|
Baseline, Months 3 and 15
|
Mean change in Gd+ lesion count
Time Frame: Baseline, Months 3 and 15
|
Increase in the number of contrast-enhancing lesions on MRI
|
Baseline, Months 3 and 15
|
Mean change in Gd+ lesion volume
Time Frame: Baseline, Months 3 and 15
|
Increase in size of contrast-enhancing lesions on MRI
|
Baseline, Months 3 and 15
|
Mean change in T2 lesion count
Time Frame: Baseline, Months 3 and 15
|
Increase in new T2 lesions on MRI
|
Baseline, Months 3 and 15
|
Mean change in T2 lesion volume
Time Frame: Baseline, Months 3 and 15
|
Increase in size of T2 lesions on MRI
|
Baseline, Months 3 and 15
|
Mean change from Baseline in T1
Time Frame: Baseline up to Month 15
|
Presence of new or enlarged T1 lesions
|
Baseline up to Month 15
|
Mean change in MSQOL-54
Time Frame: Month 3 to Month 15
|
The MSQOL-54 is health-related quality of life questionnaire that assesses the physical, mental, and social effects experienced by MS patients, as well as functional disability.
It is made up for 54 questions with a total score ranging from.0 to 100.
Higher scores indicate better quality of life.
|
Month 3 to Month 15
|
Mean whole brain and regional volume loss from Baseline
Time Frame: Baseline up to Month 15
|
Brain volume loss is a marker of progressive loss of brain structure and function.
It is a predictor of disability progression.
|
Baseline up to Month 15
|
Percentage of participants reporting treatment emergent adverse events (TEAEs) and serious adverse events
Time Frame: Baseline up to Month 15
|
Adverse events (TEAEs) and serious adverse events will be reported at each visit
|
Baseline up to Month 15
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- COMB157GUS09
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Relapsing-Remitting Multiple Sclerosis
-
BiogenWithdrawnRelapsing-Remitting Multiple Sclerosis | Relapsing Forms of Multiple Sclerosis
-
BiogenAbbVieTerminatedMultiple Sclerosis | Relapsing-Remitting Multiple SclerosisUnited States, Denmark, Italy, United Kingdom, Czechia, Canada, Hungary, Spain, Australia, Israel, Georgia, Serbia, Russian Federation, Ukraine, India, Poland, Brazil, France, Argentina, Germany, Greece, Ireland, Mexico, Moldova, Republic... and more
-
EMD SeronoPfizerCompletedRelapsing-remitting Multiple SclerosisUnited States, United Kingdom, Argentina, Austria, Brazil, France, Germany, Italy, Netherlands, Russian Federation, Spain, Switzerland
-
National Institute of Allergy and Infectious Diseases...Immune Tolerance Network (ITN)CompletedRelapsing-Remitting Multiple SclerosisUnited States
-
BiogenTerminatedRelapsing-Remitting Multiple SclerosisUnited States, Spain, Germany, Australia, Sweden, Czechia, France, Italy, United Kingdom
-
Novartis PharmaceuticalsWithdrawnMultiple Sclerosis (Relapsing Remitting)
-
Genzyme, a Sanofi CompanyTerminatedRelapsing-remitting Multiple SclerosisSweden, Poland, Russian Federation, United States, Canada
-
Novartis PharmaceuticalsCompletedRelapsing-remitting Multiple SclerosisGermany
-
Mitsubishi Tanabe Pharma CorporationCompletedRelapsing-remitting Multiple SclerosisCroatia, Bulgaria, Czech Republic, Italy, Russian Federation, Spain, United Kingdom, Germany, Lithuania, Poland, Belgium, Hungary, Serbia, Finland, Ukraine, Switzerland, Canada, Turkey
-
BiogenCompletedRelapsing-Remitting Multiple SclerosisUnited States
Clinical Trials on Ofatumumab
-
GlaxoSmithKlineCompletedMultiple SclerosisUnited States, Bulgaria, Russian Federation, Spain, Germany, Czechia, Netherlands, Norway, Italy, Canada, Denmark
-
GlaxoSmithKlineCompleted
-
GlaxoSmithKlineCompletedLeukaemia, Lymphocytic, Chronic and Lymphoma, FollicularJapan
-
GlaxoSmithKlineTerminatedArthritis, RheumatoidUnited States, Denmark, Hungary, United Kingdom, Poland
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Completed
-
GlaxoSmithKlineCompletedLeukaemia, Lymphocytic, Chronic
-
Novartis PharmaceuticalsCompleted
-
Fondazione Italiana Linfomi ONLUSCompletedFollicular Lymphoma, Grade 1 | Follicular Lymphoma, Grade 2 | Follicular Lymphoma Grade 3AItaly
-
Novartis PharmaceuticalsRecruitingMultiple Sclerosis (MS)France
-
Gruppo Italiano Malattie EMatologiche dell'AdultoActive, not recruitingLeukemia, Lymphoblastic, ChronicItaly